Interstitial lung disease associated with capmatinib therapy in a patient with non ‐small cell lung cancer harboring a skipping mutation of MET exon 14

Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non ‐small cell lung cancer (NSCLC) positive for skipping mutations ofMET exon 14 (METex14). Here we report a case of capmatinib ‐induced ILD in a patient with NSCLC harboring a skipping mutation ofMETex14. Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non –small cell lung cancer (NSCLC) positive for skipping mutations ofMET exon 14 (METex14). Drug ‐induced interstitial lung disease (ILD) is a relatively rare, but potentially serious, side effect of TKIs administered for lung cancer treatment. Here we report a case of capmatinib‐induced ILD in a patient with NSCLC harboring aMETex14 skipping mutation. Capmatinib should be immediately discontinued if ILD is suspected, and treatment with corticosteroid should be considered.

Source: Thoracic Cancer - December 21, 2020 Category: Cancer & Oncology Authors: Hiroaki Kanemura, Masayuki Takeda, Shigeki Shimizu, Kazuhiko Nakagawa Tags: CASE REPORT Source Type: research